Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab effect on pruritus neuro-mechanisms in atopic dermatitis
NCT04823130Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, open-label trial of dupilumab in atopic dermatitis (AD) (2 arms), sponsored by Sanofi. Primary endpoints: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17 and Percentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04823130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823130.